![Boehringer Ingelheim / Science / Idiopathic pulmonary fibrosis / Pharmaceutical industry / Pulmonary fibrosis / Clinical trial / Usual interstitial pneumonia / Pharmacology / Pharmaceutical sciences / Health Boehringer Ingelheim / Science / Idiopathic pulmonary fibrosis / Pharmaceutical industry / Pulmonary fibrosis / Clinical trial / Usual interstitial pneumonia / Pharmacology / Pharmaceutical sciences / Health](https://www.pdfsearch.io/img/e72c7219660c561bbc9ba2def874c332.jpg)
| Document Date: 2014-01-30 18:39:08 Open Document File Size: 200,96 KBShare Result on Facebook
City Ingelheim / Durham / / Company Duke Databank / Ridgefield / Boehringer Ingelheim Pharmaceuticals Inc. / Collaborative Partnership / Boehringer Ingelheim Corporation / / Country Germany / United States / / Currency USD / EUR / / Facility Duke Clinical Research Institute / About Duke Clinical Research Institute The Duke Clinical Research Institute / / IndustryTerm biomarker bank / manufacturing / pharmaceutical / / MedicalCondition disease / idiopathic pulmonary fibrosis / shortness of breath / pulmonary fibrosis / lung disease / progressive and fatal lung disease / inflammation / fibrosis / / Organization Duke Clinical Research Institute / Duke University Medical School / FDA / Division of Pulmonary / Allergy / and Critical Care Medicine / / Person Scott Palmer / Tunde Otulana / / Position director of Pulmonary Research / senior vice president / Clinical Development and Medical Affairs / associate professor / / ProvinceOrState North Carolina / Connecticut / / PublishedMedium Critical Care Medicine / / Technology geriatrics / genomics / proteomics / / URL www.us.boehringer-ingelheim.com / www.dcri.org / /
SocialTag |